Abstract
Human induced pluripotent stem (iPS) cells are a promising source of autologous cardiomyocytes to repair and regenerate myocardium for treatment of heart disease. In this study, we describe a method for enhanced cardiomyocyte production from human iPS cells by treating embryoid bodies with a histone deacetylase inhibitor, trichostatin A (TSA), together with activin A and bone morphogenetic protein (BMP)-4. The resulting cardiomyocytes expressed cardiac-specific transcription factors and contractile proteins at both gene and protein levels. Functionally, the contractile embryoid bodies (EBs) displayed calcium cycling and were responsive to the chronotropic agents isoprenaline (0.1 μM) and carbachol (1 μM). The cardiomyocytes derived from human iPS cells may be used to engineer functional cardiac muscle tissue for studying pathophysiology of cardiac disease, for drug discovery test beds, and potentially for generation of cardiac grafts to surgically replace damaged myocardium.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
van der Heyden MA, Jonsson MK (2012) Personalized medicine and the role of induced pluripotent stem cells. Cardiovasc Res 95:395–396
Verma V, Purnamawati K, Manasi et al (2013) Steering signal transduction pathway towards cardiac lineage from human pluripotent stem cells: a review. Cell Signal 25:1096–1107
Lim SY, Sivakumaran P, Crombie DE et al (2013) Trichostatin A enhances differentiation of human induced pluripotent stem cells to cardiogenic cells for cardiac tissue engineering. Stem Cells Transl Med 2:715–725
Hosseinkhani M, Hasegawa K, Ono K et al (2007) Trichostatin A induces myocardial differentiation of monkey ES cells. Biochem Biophys Res Commun 356:386–391
Kawamura T, Ono K, Morimoto T et al (2005) Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J Biol Chem 280:19682–19688
Kaichi S, Hasegawa K, Takaya T et al (2010) Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res 88:314–323
Vanhaecke T, Papeleu P, Elaut G et al (2004) Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11:1629–1643
Yu J, Vodyanik MA, Smuga-Otto K et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920
Liu J, Verma PJ, Evans-Galea MV et al (2011) Generation of induced pluripotent stem cell lines from Friedreich ataxia patients. Stem Cell Rev 7:703–713
Acknowledgment
These studies were supported by grants from the National Heart Foundation and National Health and Medical Research Council of Australia (1024817; 1056589). GJD is a Principal Research Fellow of NHMRC and AP is a Career Development Fellow of NHMRC. Support is also provided by the JR and JO Wicking Trust, Friedreich’s Ataxia Research Association (research grant and 2012 Keith Michael Andrus Cardiac Research Award), Tony and Gwyneth Lennon Foundation, and the Victorian State Government’s Department of Innovation, Industry and Regional Development’s Operational Infrastructure Support Program.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lim, S.Y., Sivakumaran, P., Crombie, D.E., Dusting, G.J., Pébay, A., Dilley, R.J. (2014). Enhancing Human Cardiomyocyte Differentiation from Induced Pluripotent Stem Cells with Trichostatin A. In: Turksen, K., Nagy, A. (eds) Induced Pluripotent Stem (iPS) Cells. Methods in Molecular Biology, vol 1357. Humana Press, New York, NY. https://doi.org/10.1007/7651_2014_160
Download citation
DOI: https://doi.org/10.1007/7651_2014_160
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3054-8
Online ISBN: 978-1-4939-3055-5
eBook Packages: Springer Protocols